Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Arrhythmias

Free Subscription Articles published in J Thromb Thrombolysis Retrieve available abstracts of 84 articles: HTML format

Single Articles

April 2024
1. MURAKAMI Y, Todo K, Uchida K, Yamagami H, et al
   One-year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after acute large vessel occlusion stroke.
   J Thromb Thrombolysis. 2024;57:622-629.
   PubMed     Abstract available
   
   
   
2. MWITA JC, Francis JM, Pillay C, Ogah OS, et al
   Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa.
   J Thromb Thrombolysis. 2024;57:613-621.
   PubMed     Abstract available
   
   
   
3. AKHAN O, Boz M, Guzel T, Kis M, et al
   Discrimination of the acute pulmonary embolism subtypes based on the novel MAPH score.
   J Thromb Thrombolysis. 2024;57:683-690.
   PubMed     Abstract available
   
   
   March 2024
4. TRUONG B, Hornsby L, Fox B, Chou C, et al
   Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database.
   J Thromb Thrombolysis. 2024 Mar 20. doi: 10.1007/s11239-024-02958.
   PubMed     Abstract available
   
   
   February 2024
5. GJERMENI D, Anfang V, Vetter H, Szabo S, et al
   Low on-clopidogrel ADP- and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study.
   J Thromb Thrombolysis. 2024 Feb 12. doi: 10.1007/s11239-023-02937.
   PubMed     Abstract available
   
   
   
6. ZHOU Q, Liu X, Gu ZC, Yang X, et al
   Short-term antiplatelet versus anticoagulant therapy after left atrial appendage closure: a systematic review and meta-analysis.
   J Thromb Thrombolysis. 2024;57:194-203.
   PubMed     Abstract available
   
   
   January 2024
7. DE LUCENA LA, Freitas MAA, Souza AKC, Silva CHA, et al
   Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials.
   J Thromb Thrombolysis. 2024 Jan 28. doi: 10.1007/s11239-023-02945.
   PubMed     Abstract available
   
   
   
8. TRILLER DM, Wilson AS, Allen AL, Burnett AE, et al
   Digital dashboards for direct oral anticoagulant surveillance, intervention and operational efficiency: uptake, obstacles, and opportunities.
   J Thromb Thrombolysis. 2024;57:107-116.
   PubMed     Abstract available
   
   
   December 2023
9. D'ANNA L, Ornello R, Foschi M, Romoli M, et al
   Outcomes of mechanical thrombectomy in acute stroke patients with atrial fibrillation detected after stroke versus known atrial fibrillation.
   J Thromb Thrombolysis. 2023 Dec 21. doi: 10.1007/s11239-023-02923.
   PubMed     Abstract available
   
   
   
10. SALMASI S, Safari A, De Vera MA, Hogg T, et al
    Adherence to direct or vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a long-term observational study.
    J Thromb Thrombolysis. 2023 Dec 16. doi: 10.1007/s11239-023-02921.
    PubMed     Abstract available
    
    
    November 2023
11. MIZOBUCHI S, Kojima K, Miyagawa M, Tanaka Y, et al
    Association between aortic thrombi detected using non-obstructive general angioscopy and atrial fibrillation.
    J Thromb Thrombolysis. 2023 Nov 28. doi: 10.1007/s11239-023-02917.
    PubMed     Abstract available
    
    
    
12. WESTREICH R, Tsaban G, Barrett O, Kezerle L, et al
    Estimated glomerular filtration rate and the risk of stroke in individuals with diabetes mellitus and atrial fibrillation insight from a large contemporary population study.
    J Thromb Thrombolysis. 2023 Nov 9. doi: 10.1007/s11239-023-02913.
    PubMed     Abstract available
    
    
    October 2023
13. LEIVA O, How J, Grevet J, Brunner A, et al
    In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and atrial fibrillation: insights from the National Readmissions Database.
    J Thromb Thrombolysis. 2023 Oct 15. doi: 10.1007/s11239-023-02900.
    PubMed     Abstract available
    
    
    
14. LIU G, Chen T, Zhang X, Hu B, et al
    Causal effect of atrial fibrillation on pulmonary embolism: a mendelian randomization study.
    J Thromb Thrombolysis. 2023 Oct 15. doi: 10.1007/s11239-023-02903.
    PubMed     Abstract available
    
    
    
15. DING WY, Fawzy AM, Romiti GF, Proietti M, et al
    Correction: Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
    J Thromb Thrombolysis. 2023 Oct 9. doi: 10.1007/s11239-023-02904.
    PubMed    
    
    
    September 2023
16. LILJA J, Sjalander A, Sjalander S
    Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants.
    J Thromb Thrombolysis. 2023 Sep 13. doi: 10.1007/s11239-023-02890.
    PubMed     Abstract available
    
    
    August 2023
17. LIN Y, Chao TF, Tsai ML, Tseng CJ, et al
    Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study.
    J Thromb Thrombolysis. 2023 Aug 21. doi: 10.1007/s11239-023-02885.
    PubMed     Abstract available
    
    
    
18. RUSIN G, Konieczynska M, Natorska J, Malinowski KP, et al
    Low bleeding acceptance is associated with increased death risk in patients with atrial fibrillation on oral anticoagulation.
    J Thromb Thrombolysis. 2023 Aug 19. doi: 10.1007/s11239-023-02878.
    PubMed     Abstract available
    
    
    
19. DING WY, Fawzy AM, Romiti GF, Proietti M, et al
    Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
    J Thromb Thrombolysis. 2023 Aug 11. doi: 10.1007/s11239-023-02866.
    PubMed     Abstract available
    
    
    
20. ATWATER BD, Guo JD, Keshishian A, Delinger R, et al
    Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2023 Aug 2. doi: 10.1007/s11239-023-02838.
    PubMed     Abstract available
    
    
    
21. ATWATER BD, Di Fusco M, Keshishian A, Delinger R, et al
    Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2023 Aug 2. doi: 10.1007/s11239-023-02855.
    PubMed     Abstract available
    
    
    July 2023
22. JIANG M, Wang C, Zhang Y
    Comparison of early and delayed anticoagulation therapy after ischemic stroke in patients with atrial fibrillation: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2023 Jul 28. doi: 10.1007/s11239-023-02872.
    PubMed     Abstract available
    
    
    
23. HSU CC, Chen CC, Chou CY, Chen KH, et al
    Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease.
    J Thromb Thrombolysis. 2023 Jul 15. doi: 10.1007/s11239-023-02859.
    PubMed     Abstract available
    
    
    
24. BRANCO DR, Alves M, Severiano E Sousa C, Costa J, et al
    Direct oral anticoagulants vs vitamin K antagonist on dementia risk in atrial fibrillation: systematic review with meta-analysis.
    J Thromb Thrombolysis. 2023 Jul 5. doi: 10.1007/s11239-023-02843.
    PubMed     Abstract available
    
    
    
25. HAYAT A, Sjalander A, Wallvik J
    Direct oral anticoagulants: patient reported adherence and minor bleedings.
    J Thromb Thrombolysis. 2023;56:55-64.
    PubMed     Abstract available
    
    
    June 2023
26. VIRK ZM, Richardson TL, Al-Samkari H
    Antithrombotic therapy for atrial fibrillation in hereditary hemorrhagic telangiectasia.
    J Thromb Thrombolysis. 2023 Jun 20. doi: 10.1007/s11239-023-02839.
    PubMed     Abstract available
    
    
    May 2023
27. IKENOUCHI H, Koge J, Tanaka T, Yamaguchi E, et al
    P-wave terminal force in lead V(1) and atrial fibrillation burden in cryptogenic stroke with implantable loop recorders.
    J Thromb Thrombolysis. 2023 May 2. doi: 10.1007/s11239-023-02816.
    PubMed     Abstract available
    
    
    
28. TRAN E, Ledbetter LE
    A retrospective evaluation of direct oral anticoagulant (DOAC) management strategies in patients with cancer on active chemotherapy.
    J Thromb Thrombolysis. 2023;55:721-728.
    PubMed     Abstract available
    
    
    April 2023
29. WANG X, Wen D, Chen Y, You C, et al
    Anticoagulation medication in nontraumatic intracranial hemorrhage survivors with atrial fibrillation.
    J Thromb Thrombolysis. 2023 Apr 6. doi: 10.1007/s11239-023-02804.
    PubMed     Abstract available
    
    
    March 2023
30. CEREJA F, Alves M, Ferreira JJ, Caldeira D, et al
    Atrial fibrillation risk on Parkinson's disease - a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2023 Mar 25. doi: 10.1007/s11239-023-02792.
    PubMed     Abstract available
    
    
    
31. BERTEOTTI M, Gori AM, Giusti B, Fortini A, et al
    Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.
    J Thromb Thrombolysis. 2023 Mar 11. doi: 10.1007/s11239-023-02784.
    PubMed     Abstract available
    
    
    February 2023
32. CLINE L, Generoso EMG, D'Apice N, Dellinger SK, et al
    Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance < 30 mL/min.
    J Thromb Thrombolysis. 2023;55:355-364.
    PubMed     Abstract available
    
    
    
33. SIEGAL DM, Freedman D, Ansell J
    Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review.
    J Thromb Thrombolysis. 2023;55:197-202.
    PubMed     Abstract available
    
    
    
34. COSTA LSD, Alsultan MM, Hincapie AL, Guo JJ, et al
    Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020.
    J Thromb Thrombolysis. 2023;55:339-345.
    PubMed     Abstract available
    
    
    January 2023
35. DECAMILLO D, Haymart B, Kong X, Kaatz S, et al
    Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation.
    J Thromb Thrombolysis. 2023 Jan 30. doi: 10.1007/s11239-023-02777.
    PubMed     Abstract available
    
    
    
36. JANSSON M, Sjalander S, Sjogren V, Bjorck F, et al
    Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
    J Thromb Thrombolysis. 2023 Jan 6. doi: 10.1007/s11239-022-02763.
    PubMed     Abstract available
    
    
    
37. WANG K, Lu Y, Simegn MA, Xue H, et al
    Use of SAMe-TT(2)R(2) in a racially diverse anticoagulation clinic: prediction of optimal anticoagulation.
    J Thromb Thrombolysis. 2023;55:175-180.
    PubMed     Abstract available
    
    
    
38. FELDEISEN D, Alexandris-Souphis C, Haymart B, Gu X, et al
    Higher OAK (Oral Anticoagulation Knowledge) score at baseline associated with better TTR (Time in Therapeutic Range) in patients taking warfarin.
    J Thromb Thrombolysis. 2023;55:141-148.
    PubMed     Abstract available
    
    
    
39. POLZIN A, Helten C, Metzen D, Zako S, et al
    TAVR: nemesis of NOACs?
    J Thromb Thrombolysis. 2023;55:181-184.
    PubMed     Abstract available
    
    
    
40. AMIRTABAR A, Vazquez SR, Saunders J, Witt DM, et al
    Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants.
    J Thromb Thrombolysis. 2023;55:185-188.
    PubMed     Abstract available
    
    
    December 2022
41. WANG M, Yang Y, Luan M, Wang Y, et al
    Role of cerebral microbleeds in acute ischemic stroke and atrial fibrillation.
    J Thromb Thrombolysis. 2022 Dec 26. doi: 10.1007/s11239-022-02761.
    PubMed     Abstract available
    
    
    
42. HANTRAKUN N, Wongcharoen W, Thiankhaw K, Norasetthada L, et al
    Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes.
    J Thromb Thrombolysis. 2022 Dec 9. doi: 10.1007/s11239-022-02747.
    PubMed     Abstract available
    
    
    
43. CARBONE A, Bottino R, Attena E, Parisi V, et al
    Clinical impact of oral anticoagulation among octogenarians with atrial fibrillation and anaemia.
    J Thromb Thrombolysis. 2022 Dec 6. doi: 10.1007/s11239-022-02740.
    PubMed     Abstract available
    
    
    November 2022
44. LIANOS I, Varlamos C, Benetou DR, Mantis C, et al
    Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention.
    J Thromb Thrombolysis. 2022 Nov 12. pii: 10.1007/s11239-022-02723.
    PubMed     Abstract available
    
    
    October 2022
45. YE TTS, Siah QZ, Tan BYQ, Ho JSY, et al
    Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2022 Oct 3. pii: 10.1007/s11239-022-02713.
    PubMed     Abstract available
    
    
    September 2022
46. SERRAO A, Malfona F, Assanto GM, Orellana MGC, et al
    Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies.
    J Thromb Thrombolysis. 2022 Sep 20. pii: 10.1007/s11239-022-02702.
    PubMed     Abstract available
    
    
    June 2022
47. NOVAK AR, Shakowski C, Trujillo TC, Wright GC, et al
    Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.
    J Thromb Thrombolysis. 2022 Jun 10. pii: 10.1007/s11239-022-02668.
    PubMed     Abstract available
    
    
    May 2022
48. LIP GYH, Keshishian A, Kang A, Luo X, et al
    Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
    J Thromb Thrombolysis. 2022 May 17. pii: 10.1007/s11239-022-02660.
    PubMed     Abstract available
    
    
    April 2022
49. MARTINEZ KA, Eckman MH, Pappas MA, Rothberg MB, et al
    Prescribing of anticoagulation for atrial fibrillation in primary care.
    J Thromb Thrombolysis. 2022 Apr 21. pii: 10.1007/s11239-022-02655.
    PubMed     Abstract available
    
    
    
50. DING WY, Rivera-Caravaca JM, Marin F, Roldan V, et al
    Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial.
    J Thromb Thrombolysis. 2022 Apr 15. pii: 10.1007/s11239-022-02638.
    PubMed     Abstract available
    
    
    
51. FROL S, Hudnik LK, Sernec LP, Sabovic M, et al
    Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status.
    J Thromb Thrombolysis. 2022;53:607-615.
    PubMed     Abstract available
    
    
    
52. DECAMILLO D, Haymart B, Barnes GD
    Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
    J Thromb Thrombolysis. 2022;53:601-606.
    PubMed     Abstract available
    
    
    February 2022
53. POTERE N, Candeloro M, Porreca E, Marinari S, et al
    Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone.
    J Thromb Thrombolysis. 2022;53:346-351.
    PubMed     Abstract available
    
    
    
54. MEADOR S, Dyke S, Togami J, Kuskov B, et al
    Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics.
    J Thromb Thrombolysis. 2022;53:436-445.
    PubMed     Abstract available
    
    
    
55. GALLI M, Gargiulo G
    Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment.
    J Thromb Thrombolysis. 2022;53:495-498.
    PubMed    
    
    
    January 2022
56. BAI Y, Liu XY, Liu Y, Guo SD, et al
    Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation patients.
    J Thromb Thrombolysis. 2022 Jan 24. pii: 10.1007/s11239-021-02622.
    PubMed     Abstract available
    
    
    October 2021
57. LV WH, Dong JZ, Du X, Hu R, et al
    Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
    J Thromb Thrombolysis. 2021 Oct 22. pii: 10.1007/s11239-021-02588.
    PubMed     Abstract available
    
    
    
58. BEWERSDORF JP, Parmar N, Israel GM, Gettinger SN, et al
    Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases.
    J Thromb Thrombolysis. 2021;52:854-862.
    PubMed     Abstract available
    
    
    
59. CHEN Y, Zhang Y, Qu L, Huang W, et al
    Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure.
    J Thromb Thrombolysis. 2021;52:872-879.
    PubMed     Abstract available
    
    
    
60. NISLY SA, Mihm AE, Gillette C, Davis KA, et al
    Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:817-827.
    PubMed     Abstract available
    
    
    
61. SADIQ H, Hoque L, Shi Q, Manning G, et al
    SUPPORT-AF III: supporting use of AC through provider prompting about oral anticoagulation therapy for AF.
    J Thromb Thrombolysis. 2021;52:808-816.
    PubMed     Abstract available
    
    
    September 2021
62. PAPANASTASIOU A, Kartas A, Samaras A, Vrana E, et al
    Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 25. pii: 10.1007/s11239-021-02571.
    PubMed     Abstract available
    
    
    
63. WANG CL, Wu VC, Tu HT, Huang YT, et al
    Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 23. pii: 10.1007/s11239-021-02570.
    PubMed     Abstract available
    
    
    
64. OBI CA, Bulsara K, Izard S, Delicce A, et al
    Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall.
    J Thromb Thrombolysis. 2021 Sep 4. pii: 10.1007/s11239-021-02555.
    PubMed     Abstract available
    
    
    
65. CHEN J, Zhou M, Wang H, Zheng Z, et al
    Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score.
    J Thromb Thrombolysis. 2021 Sep 2. pii: 10.1007/s11239-021-02554.
    PubMed     Abstract available
    
    
    August 2021
66. MENDOZA PA, McIntyre WF, Belley-Cote EP, Wang J, et al
    Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.
    J Thromb Thrombolysis. 2021 Aug 2. pii: 10.1007/s11239-021-02530.
    PubMed     Abstract available
    
    
    
67. AFZAL S, Zaidi STR, Merchant HA, Babar ZU, et al
    Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting.
    J Thromb Thrombolysis. 2021;52:646-653.
    PubMed     Abstract available
    
    
    
68. ROMOLI M, Marchetti G, Bernardini F, Urbinati S, et al
    Switching between direct oral anticoagulants: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:560-566.
    PubMed     Abstract available
    
    
    
69. BASS ME, Kiser TH, Page RL 2nd, McIlvennan CK, et al
    Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus.
    J Thromb Thrombolysis. 2021;52:517-522.
    PubMed     Abstract available
    
    
    July 2021
70. LI RJ, Caughey GE, Shakib S
    Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jul 24. pii: 10.1007/s11239-021-02528.
    PubMed     Abstract available
    
    
    
71. KAO CC, Wang T, Parulekar AD
    Need for anticoagulation and use of direct oral anticoagulants in lung transplant recipients.
    J Thromb Thrombolysis. 2021;52:232-238.
    PubMed     Abstract available
    
    
    
72. ROSSIER C, Spoutz P, Schaefer M, Allen A, et al
    Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management.
    J Thromb Thrombolysis. 2021;52:200-208.
    PubMed     Abstract available
    
    
    
73. WALLVIK N, Renlund H, Sjalander A
    Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants.
    J Thromb Thrombolysis. 2021;52:315-323.
    PubMed     Abstract available
    
    
    
74. SYLVESTER KW, Wagner C, Lewin A, Fanikos J, et al
    Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience.
    J Thromb Thrombolysis. 2021;52:158-160.
    PubMed    
    
    
    June 2021
75. LU X, Chen T, Liu G, Guo Y, et al
    Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jun 15. pii: 10.1007/s11239-021-02490.
    PubMed     Abstract available
    
    
    May 2021
76. PIAZZA G, Hurwitz S, Goldhaber SZ
    Stroke risk factors and outcomes among hospitalized women with atrial fibrillation.
    J Thromb Thrombolysis. 2021 May 26. pii: 10.1007/s11239-021-02482.
    PubMed     Abstract available
    
    
    
77. BERNAITIS N, Badrick T, Anoopkumar-Dukie S
    Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
    J Thromb Thrombolysis. 2021 May 7. pii: 10.1007/s11239-021-02466.
    PubMed     Abstract available
    
    
    
78. GUNER A, Kalcik M, Gunduz S, Gursoy MO, et al
    The relationship between incomplete surgical obliteration of the left atrial appendage and thromboembolic events after mitral valve surgery (from the ISOLATE Registry).
    J Thromb Thrombolysis. 2021;51:1078-1089.
    PubMed     Abstract available
    
    
    
79. MARCATTO L, Boer B, Sacilotto L, Olivetti N, et al
    Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range.
    J Thromb Thrombolysis. 2021;51:1043-1049.
    PubMed     Abstract available
    
    
    April 2021
80. VINEREANU D, Napalkov D, Bergler-Klein J, Benczur B, et al
    Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    J Thromb Thrombolysis. 2021 Apr 30. pii: 10.1007/s11239-021-02450.
    PubMed     Abstract available
    
    
    
81. BARTOLAZZI F, Ribeiro ALP, de Sousa WJFN, Vianna MS, et al
    Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study.
    J Thromb Thrombolysis. 2021 Apr 15. pii: 10.1007/s11239-021-02432.
    PubMed     Abstract available
    
    
    February 2021
82. GAVIN O, Grandes J, Garcia MA, Marzo C, et al
    Treatment preferences as basis for decision making in patients using direct oral anticoagulants in Spain.
    J Thromb Thrombolysis. 2021;51:475-484.
    PubMed     Abstract available
    
    
    January 2021
83. NABAVIZADEH P, Steen DL
    Highlights from the European society of cardiology congress 2020.
    J Thromb Thrombolysis. 2021;51:232-236.
    PubMed    
    
    
    July 2020
84. DIEP R, Garcia D
    Should we monitor the direct oral anticoagulants?
    J Thromb Thrombolysis. 2020;50:30-32.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Arrhythmias is free of charge.